NCT00317174View on ClinicalTrials.gov

A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

April 30, 2004

Conditions
Haemophilus Influenzae Type bTetanusWhole Cell PertussisHepatitis BDiphtheria
Interventions
BIOLOGICAL

DTPw-HBV/Hib-MenAC conjugate vaccine

Trial Locations (1)

1781

GSK Investigational Site, City of Muntinlupa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY